Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Jacob A. Rogers

Advertisement

Articles by Jacob A. Rogers

Study compares postoperative refractive accuracy of formula-modified keratometry values versus total keratometry values obtained by a swept-source OCT biometer with new-generation multivariable IOL calculation formulas

ByJacob A. Rogers
May 4th 2022

Older generation non-LVC formulas show marked improvement upon using TK values vs K, while multivariable non-LVC formulas did not consistently improve.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

    1

    4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial

    2

    Opus Genetics has Type B RMAT meeting with FDA for its gene therapy candidate, OPGx-LCA5

    3

    PolyActiva and RareSight partner to develop treatments for rare pediatric retinal diseases

    4

    Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism

    5

    Beyond The Walls: The “how and why” behind what drives today’s ophthalmologists

    • About
    • Advertise
    • Privacy
    • Editorial Info
    • Editorial Board
    • Terms and Conditions
    • Contact Us
    • Do Not Sell My Personal Information
    • Job Board
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Ophthalmology Times
    • Modern Retina
    • Optometry Times
    • Ophthalmology Times Europe
    EyeCare Network
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us